Skip to main content

Table 2 Baseline details of the 865 ICSI cycles.

From: A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection

 

hMG

(n = 299)

HP-hMG

(n = 330)

r-hFSH

(n = 236)

p value

Mean age, years (± SD)

32.5 (± 5.3)a

34.0 (± 4.7)b

34.3 (± 4.8)c

< 0.001

(a vs b, c)

   ≤35 years, n (%)

213 (71.2)a

198 (60.0)b

142 (60.2)c

0.005

(a vs b, c)

   >35 years, n (%)

86 (28.8)a

132 (40.0)b

94 (39.8)c

0.005

(a vs b, c)

Indication, n (%)

    

   Male factor only

111 (37.1)

99 (30.0)

76 (32.2)

0.27

   Mixed factor*

142 (47.5)

156 (47.3)

129 (54.7)

0.19

   Female factor

46 (15.4)

75 (22.7)

31 (13.1)

0.33

Treatment cycle, n (%)

    

   1st cycle

195 (65.3)

192 (58.1)

145 (61.4)

0.49

   2nd cycle

80 (26.7)

86 (26.0)

60 (25.4)

0.83

   ≥3rd cycle

24 (8.0)

52 (15.9)

31 (13.2)

0.34

Mean baseline FSH, IU/L (± SD)

6.3 (± 3.2)

6.7 (± 3.7)

6.5 (± 2.8)

0.33

   ≤35 years

6.0 (± 2.8)

6.5 (± 3.1)

6.1 (± 3.0)

0.23

   >35 years

7.2 (± 3.9)

7.2 (± 4.4)

7.3 (± 4.7)

0.69

Mean baseline LH, IU/L (± SD)

4.9 (± 4.1)

5.4 (± 4.4)

5.2 (± 3.7)

0.23

   ≤35 years

5.2 (± 4.4)

5.2 (± 4.1)

5.1 (± 3.9)

0.63

   >35 years

4.2 (± 3.0)a

5.8 (± 4.8)b

4.3 (± 3.9)c

0.004

(b vs a, c)

  1. Distribution by menotropin (hMG), highly-purified menotropin (HP-hMG) or follitropin alfa (r-hFSH), after pituitary down-regulation, in relation to the age, indication, baseline FSH and LH levels, and total number of treated cycles.
  2. *Mixed factor: male + female.
  3. FSH, follicle stimulating hormone; hMG, human menopausal gonadotropin; HP-hMG, highly-purified hMG; ICSI, intracytoplasmic sperm injection; LH, luteinizing hormone; r-hFSH, recombinant human FSH; SD, standard deviation.